Patients receiving temsirolimus/bevacizumab reported significantly higher overall mean scores in the Functional Assessment of Cancer Therapy-Kidney Symptom Index ( FKSI ) -15 and FKSI-Disease Related Symptoms subscale compared with IFN/bevacizumab ( indicating improvement ) ; however , no differences in global health outcome measures were observed .